证券代码：301602 证券简称：超研股份 公告编号：2025-046 汕头市超声仪器研究所股份有限公司 关于新增募集资金专户并签订募集资金专户存储三方监管 协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日分别召开第二届董事会第九次会议和第二届监事会第六次会议，审议通过 了《关于部分募投项目增加实施主体及募集资金专户的议案》，同意募投项目"工 业无损检测系统研发项目"的实施主体由公司增加为公司和全资子公司汕头市超 声检测科技有限公司(以下简称"超声检测")，实施地点不变，同意超声检测设 立募集资金专户，用于"工业无损检测系统研发项目"募集资金的存放、管理和 使用。同意公司以募集资金向超声检测增资 2,200 万元人民币，具体内容详见公 司在巨潮资讯网披露的《关于部分募投项目增加实施主体及募集资金专户的公告》 （公告编号：2025-040）。 近日，公司和全资子公司超声检测会同保荐机构中国银河证券股份有限公司 与创兴银行有限公司汕头分行签订了《募集资金专户存储三方监 ...

9月25日，超研股份跌0.04%，成交额4603.10万元。两融数据显示，当日超研股份获融资买入额271.72 万元，融资偿还466.80万元，融资净买入-195.08万元。截至9月25日，超研股份融资融券余额合计 9967.50万元。 截至6月30日，超研股份股东户数2.23万，较上期减少16.65%；人均流通股2456股，较上期增加 19.98%。2025年1月-6月，超研股份实现营业收入1.84亿元，同比增长15.00%；归母净利润6844.55万 元，同比增长18.50%。 分红方面，超研股份A股上市后累计派现4368.96万元。 机构持仓方面，截止2025年6月30日，超研股份十大流通股东中，华宝中证医疗ETF（512170）位居第 一大流通股东，持股191.27万股，为新进股东。南方中证1000ETF（512100）位居第二大流通股东，持 股51.45万股，为新进股东。香港中央结算有限公司位居第四大流通股东，持股47.00万股，相比上期增 加2.16万股。华夏中证1000ETF（159845）位居第七大流通股东，持股30.48万股，为新进股东。圆信永 丰聚优A（010469）位居第九大流通股东，持 ...

9月24日，超研股份涨1.52%，成交额4873.31万元。两融数据显示，当日超研股份获融资买入额293.90 万元，融资偿还1016.28万元，融资净买入-722.38万元。截至9月24日，超研股份融资融券余额合计1.02 亿元。 融资方面，超研股份当日融资买入293.90万元。当前融资余额1.02亿元，占流通市值的7.03%。 资料显示，汕头市超声仪器研究所股份有限公司位于广东省汕头市金砂路77号，成立日期1982年11月15 日，上市日期2025年1月22日，公司主营业务涉及专业从事医学影像设备、工业无损检测设备的研发、 生产和销售的国家级重点高新技术企业。主营业务收入构成为：医用超声71.16%，工业超声17.30%， 配附件5.72%，X射线4.56%，其他(补充)1.26%。 截至6月30日，超研股份股东户数2.23万，较上期减少16.65%；人均流通股2456股，较上期增加 19.98%。2025年1月-6月，超研股份实现营业收入1.84亿元，同比增长15.00%；归母净利润6844.55万 元，同比增长18.50%。 融券方面，超研股份9月24日融券偿还0.00股，融券卖出0.00股，按当日收 ...

（文章来源：证券日报） 证券日报网讯超研股份9月24日在互动平台回答投资者提问时表示，公司致力于将超声和射线技术应用 在各领域以满足用户的不同需求，超声在颅脑方面的应用是公司研发的重点之一，在这方面也已经取得 了多项专利和软件著作权，详细可查阅公司招股书和定期报告。目前公司有多种型号的超声诊断产品可 应用于颅脑方面的检查。 ...

Group 1: Company Strategy and Focus Areas - The company aims to enhance its core competitiveness through industrial investments, focusing on the medical imaging and non-destructive testing sectors [2][3] - The company is actively seeking acquisition opportunities that align with its strategic development [2][3] - The company plans to expand its product portfolio through both depth and breadth, targeting cross-sector development [2][3] Group 2: Product Development and Market Position - The company has developed a portable multi-modal medical imaging system for emergency rescue applications, integrating portable DR and ultrasound devices [3][4] - The company’s industrial ultrasonic testing equipment is widely used in aerospace, petrochemicals, energy, and transportation sectors [4][5] - Key products include multi-modal medical imaging systems, specialized ultrasound diagnostic equipment, and automated non-destructive testing devices, which are expected to drive future revenue growth [5][6] Group 3: Research and Development - The company has participated in multiple national and provincial major research projects, with details disclosed in its prospectus and periodic reports [4][5] - The company has made advancements in AI-based breast cancer screening technology, enhancing the accuracy and efficiency of early detection [5][6] Group 4: Marketing and Sales Strategy - In 2025, the company will adjust its marketing strategy, focusing on major cities like Guangzhou, Shenzhen, Shanghai, and Beijing to strengthen its domestic and overseas marketing efforts [7][8] - The company aims to enhance its marketing network by attracting high-quality domestic and international distributors and improving local customer service capabilities [7][8] Group 5: Revenue Contribution - The sales revenue from surgical robots and automated non-destructive testing equipment constitutes a significant portion of the company's overall revenue [8]

证券代码：301602 证券简称：超研股份 公告编号：2025-045 汕头市超声仪器研究所股份有限公司 关于参加广东辖区上市公司 2025 年投资者网上集体接待日 活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，汕头市超声仪器研究所股份有限公司 （以下简称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"2025 年广东辖区投资者集体接待日暨辖区上市公司中报业绩说明会活动"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周 五）15:30-17:00。届时公司高级管理人员、独立董事将在线就公司 2025 年半年 度业绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟 通与交流，欢迎广大投资者踊跃参与！ 特此公告。 汕头市超声仪器研究所股份有限公司 董事会 2025 年 9 月 16 日 ...

Core Points - The company held its second extraordinary general meeting on September 15, 2025, where multiple important resolutions were reviewed and passed with high votes [1] - The meeting utilized a combination of on-site and online voting, with a total of 105 shareholders and representatives present, representing 364,475,192 shares, which is 85.0922% of the total voting shares [1] Summary of Resolutions - Amendment of the Articles of Association: Total votes in favor were 364,364,792 shares, accounting for 99.9697% [2] - Revision of the Shareholders' Meeting Rules: Total votes in favor were 364,363,692 shares, accounting for 99.9694% [3] - Revision of the Board Meeting Rules: Total votes in favor were 364,360,392 shares, accounting for 99.9685% [3] - Revision of the Independent Director Work System: Total votes in favor were 364,361,692 shares, accounting for 99.9689% [3] - Revision of the External Guarantee Management System: Total votes in favor were 364,357,992 shares, accounting for 99.9678% [3] - Revision of the Related Party Transaction Management System: Total votes in favor were 364,368,592 shares, accounting for 99.9708% [3] - Revision of the External Investment Management System: Total votes in favor were 364,358,392 shares, accounting for 99.9680% [3] - Revision of the Controlling Shareholder and Actual Controller Behavior Norms: Total votes in favor were 364,371,492 shares, accounting for 99.9715% [3] - Revision of the Code of Conduct for Directors and Senior Management: Total votes in favor were 364,362,992 shares, accounting for 99.9692% [3] - Revision of the Fund Usage Management System: Total votes in favor were 364,359,092 shares, accounting for 99.9681% [3] - Revision of the Major Transaction Management System: Total votes in favor were 364,367,292 shares, accounting for 99.9704% [3] Abolishment of Supervisory Committee Regulations - The resolution to abolish the Supervisory Committee Meeting Rules was passed with total votes in favor of 364,373,192 shares, accounting for 99.9720% [4]

国浩律师(广州)事务所 关于汕头市超声仪器研究所股份有限公司 2025 年第二次临时股东会的法律意见 汕头市超声仪器研究所股份有限公司: 根据中国证券监督管理委员会发布的《上市公司股东会规则》(以下简称《股 东会规则》）的要求,国浩律师(广州)事务所(以下简称"本所")接受汕头市超 声仪器研究所股份有限公司(以下简称"超研股份")的委托,指派周姗姗、林嘉 豪律师(以下简称"本所律师")出席超研股份 2025 年第二次临时股东会(以下简 称"本次股东会")，对本次股东会的召集与召开程序、出席会议人员与召集人 的资格、表决程序与表决结果等重要事项出具法律意见。 本所及本所律师依据《中华人民共和国公司法》(以下简称《公司法》)、《律 师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规则(试 行)》等规定及本法律意见书出具日以前已经发生或者存在的事实,严格履行了 法定职责,遵循了勤勉尽责和诚实信用原则,进行了充分的核查验证,保证本法 律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不 存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 一、本次股东会的召集与召开 律师(广州 ...

证券代码：301602 证券简称：超研股份 公告编号：2025-044 汕头市超声仪器研究所股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、会议召开时间： （1）现场会议：2025年9月15日（星期一）15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为2025 年9月15日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为2025年9月15日9:15-15:00期间的任意时间。 2、现场会议召开地点：广东省汕头市金砂路77号汕头市超声仪器研究所股 份有限公司1楼会议室。 3、召开方式：本次股东会采取现场投票与网络投票相结合的表决方式。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一） 召开情况 4、召集人：汕头市超声仪器研究所股份有限公司董事会 5、主持人：董事长李德来先生 6、会议的召开符合相关法律、行政法规、部门规章、规范性文件和公司 ...

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant focus on the pet economy and smart medical technology [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%. The net profit attributable to the parent company was 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% [8]. Market Position and Trends - The company participated in the 97th WVC annual meeting, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2]. - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [2]. Stock Performance - On September 9, the company's stock price fell by 1.93%, with a trading volume of 71.26 million yuan and a turnover rate of 4.80%, resulting in a total market capitalization of 10.871 billion yuan [1].